Please use this identifier to cite or link to this item:
|Title:||Safety and efficacy of Ac-225-PSMA-617 in mCRPC after failure of Lu-177-PSMA|
|Authors:||FEUERECKER BENEDIKT; KNORR KARINA; BEHESHTI A; SEIDL C.; D'ALESSANDRIA C; BRUCHERTSEIFER FRANK; TAUBER R; RETZ M; WEBER WOLFGANG; MORGENSTERN ALFRED; EIBER MATTHIAS|
|Citation:||NUKLEARMEDIZIN-NUCLEAR MEDICINE vol. 58 no. 2 p. 109|
|Publisher:||SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN|
|Type:||Articles in periodicals and books|
|Abstract:||Despite the approval of several new agents metastatic castration resistant prostate cancer is still a major medical challenge. The beta-emitting Lu-177-PSMA radioligand therapy (RLT) is a new option but its antitumor effect can decrease over time. The aim of this retrospective analysis was to investigate safety and efficacy of the alpha emitting Ac-225-PSMA-617 RLT in mCRPC after Lu-177-PSMA failure.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.